Quantcast

Latest NeuroDerm Ltd. Stories

2014-08-21 16:24:23

REHOVOT, Israel, August 21, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. The company plans to use the funding to further the clinical and regulatory...

2014-08-04 08:27:58

REHOVOT, Israel, August 4, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). According to EMA guidelines, the EMA can allow products for which the centralized...

2014-03-11 08:29:26

REHOVOT, Israel, March 11, 2014 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease....


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'